Clinical trial
Saphnelo for Intravenous Infusion 300 mg Specific Use Result Study All Patient Investigation in Patients With Systemic Lupus Erythematosus
NCT05141201 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Saphnelo for Intravenous Infusion 300 mg Specific Use Result Study All Patient Investigation in Patients With Systemic Lupus Erythematosus
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- December 21, 2021
- Completion date
- March 31, 2027
- Enrollment
- 1,620 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.